Current Clinical Trials

  • ORTHOPEDICS: LIBERATE

    LIBERATE is a randomized controlled clinical trial comparing use of bupivacaine with the adjuncts dexamethasone and epinephrine to liposomal bupivacaine in interscalene nerve block for shoulder arthroplasty patients.

  • CANCER: Genomic Profiling IMPACT (MSK 12-245)

    The purpose of this genomic profiling study is to determine whether certain genes in cancer may be abnormal.

  • CANCER: HEME MSK 16-024 Leukemia Registry

    Observational Study to Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

  • CANCER: Colorectal Cancer NRG GI004

    Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

  • CANCER: Pancreatic Cancer Tyme-88-PANC

    A Phase II Multi-Center Study of SM-88 in Patients with Pancreatic Cancer Whose Disease Has Progressed or Recurred after/on First Line Chemotherapy.

  • CANCER: Brain Cancer BN003

    This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery.

  • CANCER: Lung Cancer E4512

    This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK).

  • CANCER: Lung Cancer AO81105

    This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery.

  • CANCER: Breast Cancer MSK 17-585

    The purpose of this study is to test the safety of the study drug neratinib in combination with a standard chemotherapy drug called capecitabine at different doses to find out what effects, if any, it has on people.

  • PSYCH: Neural Architecture of Social Emotional Processing and Regulation in Autism Spectrum Disorder

    This study delineates the temporal dynamics of the neural networks underlying social behaviors and emotional processing in relation to the diagnosis of autism spectrum disorder (ASD) and its social traits.

  • PSYCH: Major Depressive Disorder - ESKETINSUI2002 (Janssen)

    Clinical trial to examine the efficacy and safety of an investigational medication - esketamine (given as a nasal spray) - in adolescents hospitalized with depression and suicidal ideation.

  • CANCER: Brain Tumors MSK 17-261

    The purpose of this study is to test any good and bad effects of a study drug called abemaciclib (LY2835219) in patients with recurrent brain tumors.

  • CANCER: Breast Cancer S1418

    This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

  • PSYCH: Post-Traumatic Stress Disorder - 331-201-00071 (Otsuka)

    Clinical trial to examine the efficacy and safety of brexpriprazole combined with sertraline as treatment for adults with posttraumatic stress disorder.

  • CANCER: Gynecologic Cancer GOG 3018/VBL-111-701

    The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.

  • PSYCH: Major Depressive Disorder 1402-0011 (Boehringer-Ingelheim)

    Clinical trial to examine the efficacy and safety of an investigational medication compound compared to placebo in patients with Major Depressive Disorder.

  • CANCER: Gynecologic Cancer MSK 17-180

    The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.

  • CANCER: Pancreatic Cancer MSK 19-239

    A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

  • CANCER: Breast Cancer NRG BR005

    This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery may help to check if chemotherapy destroyed the breast cancer cells and may be compared to the tumor removed during surgery to check if they are the same.

  • The COVID-19 and Cancer Consortium (CCC19) Registry

    In late 2019 and early 2020, the world witnessed the outbreak of respiratory disease caused by a novel coronavirus first detected in Wuhan, China, and now a pandemic. The virus has been named SARS-CoV-2, and the disease it causes, coronavirus disease 2019, abbreviated as COVID-19. There are now over 300,000 persons diagnosed with this disease around the world, and nearly 14,000 deaths.

  • CANCER: Leukemia D8220C00008 (Heme)

    A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects With Chronic Lymphocytic Leukemia.

  • CANCER: Thoracic Cancer LUNGMAP

    This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400).

  • CANCER: Neuro MSK 18-400

    This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.

  • CANCER: Thoracic Cancer S1900B

    This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

  • CANCER: RadOnc MSK 18-359

    Drugs called checkpoint inhibitors help the immune system fight cancer. When the effectiveness of these drugs wears off, it may be possible to renew their effectiveness by combining it with a special type of radiation therapy called stereotactic body radiation therapy (SBRT).

  • CANCER: Thoracic Cancer D4194C00008

    A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patient’s post-CRT, while on durvalumab.

  • CANCER: Prostate Cancer MK-3475-991

    This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus ADT in participants with mHSPC.

  • CANCER: Lymphoma EZH-302

    Stage 1 is a safety run-in phase, stage 2 is an efficacy and safety phase for an assessment of the EZH2 Mutant Type population and overall FL population regardless of EZH2 mutation status, and optional stage 3 with efficacy and safety phase for subjects with EZH2 mutation.

  • CANCER: Pancreatic Cancer UVA-PC-PD101 (GI)

    The purpose of this clinical trial is to study an experimental drug called pembrolizumab or MK-3475 for use in combination with chemotherapy and radiation therapy for patients with resectable (surgical removal) or borderline resectable pancreatic cancer.

  • CANCER: Renal Cell WO41994 (GU)

    This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who experienced radiographic tumor progression during or after Immune Checkpoint Inhibitor (ICI) treatment in the metastatic setting.

  • CANCER: Endometrial Cancer MSK 20-067

    This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.

  • CANCER: Gynecologic Cancer NRG-GY009 (Gyn)

    This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent).

  • CANCER: Ovarian Cancer NRG-CC008

    This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1 mutations.

  • CANCER: Radiation Oncology MSK 18-486

    This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

  • CANCER: Thoracic Cancer GO41892

    This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients with metastatic NSCLC, with no sensitizing EGFR mutation or ALK translocation, who have progressed following treatment with platinum-containing chemotherapy and anti-PD-L1/PD-1 antibody, administered concurrently or sequentially.

  • CANCER: Gynecologic Cancer NRG-GY006

    This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer.

  • CANCER: Neurologic Cancer EF-32/ TRIDENT

    To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.

  • CANCER: Thoracic Cancer MSK 19-199

    This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients with metastatic NSCLC, with no sensitizing EGFR mutation or ALK translocation, who have progressed following treatment with platinum-containing chemotherapy and anti-PD-L1/PD-1 antibody, administered concurrently or sequentially.

  • CANCER: Endometrial Cancer NRG GY018

    This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent).

  • CANCER: Liver Cancer SRN-705-005 (Phase 1)

    This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma or liver metastasis in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy.

  • CANCER: Multiple Tumor Types NRG-GY022

    This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer.

  • CANCER: Breast Cancer MSK 19-045

    The purpose of this study is to test whether patients with breast cancer who are being treated with non-anthracycline trastuzumab therapy can safely be monitored for heart related side effects less often than usual.

  • CANCER: Breast Cancer EA1181

    This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy.

  • CANCER: Bladder Cancer MSK 19-374

    This study will test the safety of BCG and gemcitabine in people who have BCG-relapsing Non-Muscle Invasive Bladder Cancer (NMIBC). The researchers will test increasing doses of gemcitabine to find the highest dose that causes few or mild side effects when combined with BCG.

  • CARDIO: Research Volunteers Wanted to Examine Vascular Function in Testicular and Hodgkins Cancer Survivors

    Research volunteers are wanted for examination of vascular function in testicular and Hodgkins cancer survivors. Participants must be 20-55 year old men previously treated for testicular cancer to be eligible. Participants who finish the study will receive free health information and financial compensation for their time.

  • PSYCH: Children of Parents with Alzheimer's Needed for Research on Brain Structure/Function

    Children of parents with alzheimer's are needed for research on brain structure/function. To be eligible individuals must be between the ages of 40 and 60, have a mother or father diagnosed with dementia/Alzheimer's after age 60, not be currently exercising, be willing to exercise 3 times per week for 6 months at Hartford Hospital, and be willing to undergo an MRI scan.

  • PSYCH: Healthy Volunteers Needed for Neuroimaging (Brain Scan) Study

    Investigators at The Anxiety Disorders Center at the Institute of Living/Hartford Hospital are recruiting participants without psychiatric problems for a neuroimaging (brain scan) study. We are offering a study that involves undergoing a neuroimaging (brain) scan while also participating in tasks that will examine your brain functioning.

  • PSYCH: Participants Needed for Sickle Cell/Brain fMRI Research Study

    This research study intends to understand how pain affects the brains of people with sickle cell disease. Healthy volunteers who are African-American and between the ages of 15-30 years are eligible. One 3-hour visit will be required and you will be compensated for your time!

  • PSYCH: Researchers seeking adolescents with and without ADHD, ages 9-18

    The Olin Neuropsychiatry Research Center at The Institute of Living is conducting a study of adolescents with ADHD ages 9-18 and healthy adolescents ages 9-18 to look at how the brain functions during decision-making in cognitive tasks. The study will require at least 1 visit to complete interviews with clinical staff and MRI scans. Qualified volunteers will be compensated $20 per hour for participation.

  • PSYCH: Researchers Seeking Adults with Autism Spectrum Disorders, Ages 18-40

    The Olin Neuropsychiatry Research Center at The IOL is conducting a study of adults with autism spectrum disorders (ASD) ages 18-40 to look at how our brains process social interactions and how it is different in individuals with ASD. The study may require two or more visits to complete interviews with clinical staff, MRI scans and an EEG. Qualified volunteers are compensated $20/hour for their time.

  • PSYCH: Healthy Adults Sought For Research Study

    The Olin Neuropsychiatry Research Center at The Institute of Living is looking for healthy adults 18-60 with no significant history of mental illness. Participation will include: interviews and questionnaires, pencil and computer games, and an MRI. Qualifying persons will be compensated $20 per hour for their time. Lunch provided.

  • PSYCH: Participants with a Family History of Alcoholism Needed for Research Study

    Are you a healthy, right-handed adult between the ages of 18 and 35? You may qualify to participate in a research study at The Olin Neuropsychiatry Research Center at the IOL. Individuals matching that description who have relatives with alcoholism or a history of alcoholism are eligible to participate in this research study.

  • PSYCH: Help for Hoarding at No Cost

    The Anxiety Disorders Center at the Institute of Living/Hartford Hospital is conducting a study for people with Hoarding Disorder.

  • PSYCH: Healthy Volunteers Needed for Research Study

    The Anxiety Disorders Center at the Institute of Living/Hartford Hospital is recruiting participants with no current or lifetime history of psychiatric problems for a research study.

  • CARDIO: PULSE Pilot Study

    The Department of Preventive Cardiology is seeking individuals with high blood pressure for an exercise training study. You may qualify if you have (or think you have) high blood pressure; 18 years or older; non-smoker; and currently exercise less than two days per week.

  • CANCER: Lung Cancer Alchemist A151216

    This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been, or will be removed by surgery.

  • CARDIO: Media and Heart Health

    Dr. Taylor from Hartford Hospital, Dr. Pescatello from the UConn Department of Kinesiology and Dr. Puhl from the UConn Rudd Center are conducting a research study to compare the effects of a short-term encounter to media videos on measures of mental and physical heart health in women.

  • CANCER: Yoga 4 Cancer

    If you are a patient at the Hartford HealthCare Cancer Institute at Hartford Hospital, or a patient with a musculoskeletal condition and a cancer history being seen through the Hartford HealthCare Bone & Joint Institute, you may be eligible for a research study investigating the benefits of yoga on mobility and quality of life.

MSK_ClinicalTrials_Ad